Seqens Seqens

X
[{"orgOrder":0,"company":"Acino Pharma AG","sponsor":"Aspen Pharmacare Holdings","pharmaFlowCategory":"D","amount":"$119.4 million","upfrontCash":"Undisclosed","newsHeadline":"Acino Acquires Selected Aspen Brands in South Africa","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals by Acino Pharma AG

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            The transaction includes Trustan, Altosec, Zuvamor, Ciavor, Grantryl and Aspen Granisetron brands. To secure uninterrupted patient access to these medicines, the parties have also signed a manufacturing and supply agreement.

            Lead Product(s): Esomeprazole Magnesium

            Therapeutic Area: Gastroenterology Product Name: Trustan

            Highest Development Status: Approved Product Type: Small molecule

            Recipient: Aspen Pharmacare Holdings

            Deal Size: $119.4 million Upfront Cash: Undisclosed

            Deal Type: Acquisition October 22, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY